CKDXF OTC
Ceryvyn Therapeutics Limited
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: -97.7%
1Y: -97.7%
3Y: -97.6%
5Y: -99.1%
$0.01
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$13.7M
52W Range0.01-0.44
Volume130
Avg Volume649
Beta1.50
Dividend—
Analyst Ratings
Company Info
CEOJeremy Max Levin Ba Zoology Dphil Mb Bchir
Employees33
SectorHealthcare
IndustryBiotechnology
IPO Date2011-10-25
Websiteceryvyn.com
117 Camberwell Road
Hawthorn East, VIC 3123
AU
Hawthorn East, VIC 3123
AU
61 3 9826 0399
About Ceryvyn Therapeutics Limited
Ceryvyn Therapeutics Ltd is a clinical-stage biopharmaceutical company developing therapies for the rare lung disease lymphangioleiomyomatosis (LAM). Its lead program, CYV-101, is a fusion protein designed to neutralize VEGF-C and VEGF-D, key signaling proteins involved in the disease. The company was formerly known as Opthea Limited.
Latest News
No recent news
Recent Insider Trades
No insider trades found